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BACKGROUND: Patients refractory for platelet
transfusions benefit from human leukocyte antigen
(HLA)-matched platelet transfusions. Differences in
ethnic background of patients and donors could hamper
the availability of sufficient numbers of HLA-matched
donors for all patients. We evaluated our HLA-matched
donor program and explored the role of ethnic
background of patients related to the number of available
donors.
METHODS: We performed a cohort study among
consecutive patients who received HLA-matched platelet
concentrates in the Netherlands between 1994 and
2017. The number of available matched donors was
determined per patient. Haplotypes were constructed
from genotypes with computer software (PyPop). Based
on haplotypes, HaploStats, an algorithm from the
National Marrow Donor Program, was used to assess
the most likely ethnic background for patients with 5 or
fewer and 30 or more donors.
RESULTS: HLA typing was available for 19,478 donors
in September 2017. A total of 1206 patients received
12,350 HLA-matched transfusions. A median of
83 (interquartile range, 18-266) donors were available
per patient. For 95 (10.3%) patients, 5 or fewer donors
were available. These patients were more likely to have
an African American background, whereas patients with
30 or more donors were more often from Caucasian
origin, compared with Caucasian origin for patients with
30 donors.
CONCLUSION: Adequate transfusion support could be
guaranteed for most but not all refractory patients. More
non-Caucasian donors are required to ensure the
availability of HLA-matched donors for all patients in the
Netherlands.
T
reatment of hematologic malignancies comprises
intensive chemotherapy leading to periods of
aplasia, which renders the patient transfusion
dependent for prolonged periods of time. A sub-
set of these patients develops refractoriness for random
platelet transfusions.
In the Dutch Blood Transfusion Guideline, this is defined
as 1-hour corrected count increment (1hCCI) of 7.5 or less after
two subsequent ABO-compatible platelet transfusions.1 The
corrected count increment was calculated according to the for-
mula: platelet count increment (×109/L) × body surface area
(m2)/number of platelets transfused (×1011).
Refractoriness is associated with an increased risk of
bleeding, prolonged hospital stay, and higher hospital
costs.2,3 In 80% to 90% of platelet refractory patients, low
1hCCIs are caused by nonimmunological factors. In 10% of
patients, immune-mediated clearance of transfused platelets
is the predominant cause of refractoriness. Alloantibodies
directed against human leukocyte antigen (HLA) Class IA or
ABBREVIATIONS: 1hCCI = 1-hour corrected count increment;
HWE = Hardy-Weinberg equilibrium.
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IB antigens account for the vast majority of immune-
mediated clearance.4,5
In a previous study, we showed that refractory patients
benefit most from a transfusion from a completely HLA-
matched, ABO-compatible donor. Products with some
degree of HLA mismatching or ABO incompatibility may
still lead to adequate corrected count increments. These
mismatches are considered acceptable according to either
antibody specificity, epitope matching, cross-reactive
groups, the effect of previous transfusions, or any combina-
tion of these strategies.6 In the Netherlands as in many
countries, most patients who are included in the HLA-
matched program have a hematologic malignancy requiring
treatment with intensive chemotherapy during which ade-
quate platelet support is needed. Our national blood supply
organization offers platelet products including HLA platelets
to all hospitals in the Netherlands. A large panel of donors
has given permission to donate apheresis platelets and has
been HLA typed. They can be requested to donate HLA-
matched single-donor apheresis platelets for specific refrac-
tory patients. At present, we recruit new donors to be HLA
typed from the 18- to 35-year-old whole blood and plasma
donor group, without further selection.
The HLA system is encoded by the major histocompati-
bility gene complex, spanning a 3-Mb region on chromo-
some 6p21. This is the most polymorphic region of the
genome, and allele frequencies differ highly among
populations. This makes HLA matching a challenging task
in genetically diverse populations. Within the United States,
it has been shown that certain HLA-A and -B alleles are
almost exclusively expressed in patients from African Ameri-
can or Asian origin, whereas these are hardly observed
among Caucasians or North American Natives.7 Moreover,
in solid-organ transplantation as well as in hematopoietic
stem cell transplantation, it has been shown that the proba-
bility of finding a sufficiently matched HLA-compatible
donor is lower for patients from ethnic minorities as com-
pared to Caucasian patients, since most registered donors
are of Caucasian origin.8,9 Therefore, a genetically diverse
HLA-typed donor population is mandatory to ensure suffi-
cient support for all patients.
We hypothesized that HLA-matched platelet support
for non-Caucasian patients is hampered in a similar way as
organ and stem cell transplantation. The Dutch Donor
InSight study was aimed to gain insight into the characteris-
tics and motivation of Dutch blood and plasma donors. This
study showed that 2.6% of the Dutch plasma and whole
blood donor population is of non-Dutch origin, whereas this
was 19.8% in the general population.10 In this study, Dutch
origin was defined as both parents born in the Netherlands,
although this definition is flawed from a genetic point of
view. Moreover, another study revealed that almost two-
thirds of our donor population lives in a geographic area
with less than 5% ethnic diversity. In addition, donors living
in an area with more than 40% ethnically diverse persons
more often resigned as a blood donor.11 This is likely to
result in a donor population that is less well tailored to meet
the needs of the 4 million first- and second-generation
immigrants currently living in the Netherlands, comprising
23.6% of the total current population of 17 million people.12
In the current study, we evaluated our HLA-matched
donor program by estimating the proportion of the nation-
wide patient population that can be supported by the cur-
rent HLA-typed donor population. In addition, we explored
the role of ethnic background of patients related to the
number of available donors.
METHODS
Design and population
We performed a cohort study using a registry of clinically
refractory patients for whom an HLA-matched product was
ordered at the Unit of Transfusion Medicine of Sanquin, the
Dutch national blood supply foundation. This registry
started in 1994 and has had nationwide coverage since
2013. An HLA-matched product can be requested for
patients with inadequate increments (1hCCI ≤7.5) on at
least two random platelet transfusions when a role for HLA
antibodies is suspected. In the current study, neonates were
excluded, as thrombocytopenia of immunological origin in
neonates is predominantly caused by transferred maternal
antibodies. All HLA-matched products were apheresis
derived, leukoreduced, stored in plasma, and irradiated
before transfusion.1
Since the start of the registry, HLA typing techniques
have improved significantly, and nowadays DNA-based typ-
ing has replaced serologic typing. We included only patients
who had been HLA typed at least at low resolution for HLA-
A and -B (DNA, two digits). We included both serologically
and genetically typed donors. For genetic analyses, we
converted serologic HLA typing into low-resolution
DNA type.
Evaluation of donor population
In general, most patients who require platelet transfusions
are being treated for a hematologic malignancy. Based on
our experience, we assume that more than five donors per
patient are required to ascertain sufficient transfusion sup-
port during chemotherapy and stem cell transplantation.
We evaluated the current HLA-typed donor population in
three different ways.
First, we determined the number of available donors,
regardless of ABO blood group, for all patients’ HLA pheno-
types. For each phenotype, a donor-to-patient combination
was categorized as matched if a patient and donor were
HLA identical or compatible (i.e., donor with homozygous
locus). In terms of Duquesnoy criteria, this comprises
Grade A, BU, and B2U matches.13 Second, we compared the
prevalence of all HLA-A and -B antigens in patients and
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donors.13 Third, we compared the haplotypes of patients
and donors. Therefore, haplotype frequencies were esti-
mated with the iterative expectation-maximization algo-
rithm, and deviation from Hardy-Weinberg proportions was
tested for patients and donors. This analysis was performed
using a software package (PyPop 0.7.0).14,15
Ethnicity
In the Netherlands, we do not register the ethnicity of our
donors. Therefore, we estimated the most likely ethnicity,
based on most likely estimated haplotype for patients and
donors with HaploStats. HaploStats is an algorithm from the
National Marrow Donor Program.16 Based on data of a large
US reference population, the prevalence of the most likely
haplotype given the observed HLA-A and HLA-B antigens is
given for different ethnic populations. We designated the
origin of our donors as African American, Asian or Pacific
Islander, Caucasian, Hispanic, or Native American,
according to the HaploStats program.17,18 The ethnicity with
the highest prevalence for a certain haplotype was deter-
mined as most likely for that patient. For this analysis, we
assumed that the distribution of the phenotypes of patients
in our registry is representative of the phenotypes in our
patient population. We estimated the ethnicity of patients
with five or fewer donors and of a random sample of
100 patients with a high number (n ≥ 30) of compatible
donors and compared the number of patients of non-
Caucasian origin in these groups. Due to privacy regula-
tions, reporting unique haplotypes was not allowed.
RESULTS
Between 1994 and 2017, an HLA-matched platelet concen-
trate was requested for 1021 refractory patients. These
patients received in total 12,350 HLA-matched transfusions,
with a median of 5 (interquartile range [IQR], 2-15) and a
maximum of 229 transfusions per patient. Patients were on
average 54.4 years old, 65.4% were female, and the majority
were treated for a malignant hematologic disease, predomi-
nantly acute leukemia (see table 1).
Available donors
In September 2017, the registry contained 19,478 HLA-typed
platelet donors, who expressed 4770 unique phenotypes,
with a median of 8 (IQR, 2-30) donors per phenotype. The
most common phenotype among the donors was homozy-
gous HLA A*01; B*08, which was expressed by 251 donors.
The 1021 patients for whom HLA-matched platelets had
been requested expressed 701 different HLA phenotypes,
with a median of 1 (IQR, 1-2) patient per phenotype. The
most common phenotype, expressed by 16 patients, was
HLA A*01, *02; B*07,*08, for which 193 identical and
582 compatible donors were available. Each patient could
be matched to a median of 83 (IQR, 18-266) identical or
compatible donors, with a maximum of 807 donors per
Fig. 1. Number of matched donors in the current donor population for all patients in the registry. The number of HLA identical or
compatible donors per patient. The dotted line is set at 20 donors.
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patient (Fig. 1). For 17 patients, all with a unique pheno-
type, no HLA-matched donors were available. For
95 (10.3%) patients, 5 or fewer HLA-matched donors could
be found, for 161 (17.5%) patients 10 or fewer, and for
251 (27.3%) patients 20 or fewer donors were regis-
tered (Fig. 1).
Fig. 2. Prevalence of HLA antigens among patients and donors. The percentage of donors with certain antigen is depicted with circles
and the gray solid line. The prevalence among patients is reflected with triangles and a black dashed line. (A) HLA-A antigens. (B) HLA-
B antigens.
TABLE 2. Hardy-Weinberg equilibrium
p value
Patients (N=1151)
A locus overall (common + lumped) 0.0005*
A locus homozygotes 0.0002*
A locus heterozygotes 0.1258
B locus overall (common + lumped) 0.0082*
B locus homozygotes 0.0000*
B locus heterozygotes 0.1102
Donors (N=19478)
A locus overall (common + lumped) 0.0944
A locus homozygotes 0.0048*
A locus heterozygotes 0.1882
B locus overall (common + lumped) 0.0299*
B locus homozygotes 0.0056*
B locus heterozygotes 0.3796
* p < 0.05.
TABLE 1. Demographics of the study population
Characteristics Total registry
Patients (n) 1021
Unique phenotypes (n) 701
Female, n (%) 666 (65.4)
Diagnosis, n (%)
Acute leukemia 404 (39.6)
Chronic leukemia 49 (4.8)
Lymphoma 51 (5.0)
Multiple myeloma 29 (2.8)
Myelodysplastic syndrome 123 (12.1)
Myelofibrosis or aplastic anemia 81 (7.9)
Benign hematologic diseases* 23 (2.3)
Solid tumor 27 (2.6)
Solid-organ transplantation 7 (0.7)
Other or unknown 166 (16.3)
* Including Glanzmann thrombasthenia, Bernard Soulier syn-
drome, Castelman’s disease, gray platelet syndrome, thalasse-
mia, polycythemia vera, autoimmune thrombocytopenia,
immune thrombocytopenia.
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Evaluation of donor population
The prevalence of HLA-A and -B antigens was comparable
among patients and donors (Fig. 2). The most likely haplo-
type among patients and donors was HLA A*01; B*08,
which was expressed by 208 patients and 3877 donors. For
47 patient haplotypes, 5 or fewer donors were available.
Fourteen unique haplotypes among patients were not
expressed by any donor. In the patient cohort, genotype fre-
quencies deviated from Hardy-Weinberg equilibrium
(HWE), with an overrepresentation of homozygotes. The
donor cohort showed less deviation. The overall test for the
genotype frequencies of the A locus of donors is in HWE.
These HWE results are summarized in Table 2.
Ethnicity
Within the donor population, 6 of the 10 most common
haplotypes were most likely from Caucasian background,
2 Native American, and 2 Hispanic. Among patients, 7 of
the 10 most common haplotypes were Caucasian, 2 Native
American, and 1 Hispanic. Caucasian was the most likely
ethnicity for 42% of patients with 30 or more donors and for
6% of patients with 5 or fewer available donors. The most
likely ethnic origin for patients with 5 or fewer donors was
African American (64%) and Asian Pacific (19%). In the
patient group with 30 or more donors 22% were Asian
Pacific and 6% were African American (Fig. 3).
DISCUSSION
Currently, almost 20,000 donors, representing 6717 unique
HLA phenotypes, are available to donate HLA-matched
platelets upon request in the Netherlands. In our experi-
ence, availability of more than five donors is required to
ensure sufficient support during intensive treatment for
hematologic malignancies. Despite nationwide coverage,
insufficient numbers of completely HLA-matched donors
were available for 10.3% of refractory patients. Lack of suffi-
cient donors could hamper adequate, intensive treatment,
and HLA-mismatched products result in lower increments
as compared to completely HLA-matched transfusions.
The prevalence of specific HLA-A and -B antigens
among these donors largely overlaps with the prevalence of
these antigens among patients. All individual HLA antigens
present in the patients’ phenotypes are represented in the
donor population as well, as we showed by simply counting
the antigens. However, this is not an adequate method to
evaluate the donor program, as the HLA system has strong
linkage disequilibrium patterns, resulting in highly
population-specific haplotypes.19,20 Thus, an adequate eval-
uation can be performed only on the haplotype level.
Estimating the haplotype frequencies in the patient
population revealed that there was an overrepresentation of
homozygotes, causing deviation from HWE. This could not
be traced back to specific antigens. In the donor population,
the A locus was in HWE, whereas this was not the case for
the B locus. This was also not specific for a single antigen.
The deviation from HWE in the patient population could be
explained by the presence of several ethnic subpopulations
within this group. The donor population is in HWE, at least
for the A antigen. This supports the finding that our donor
population is genetically less diverse (i.e., predominantly
Caucasian), whereas our patients are more representative of
the admixed population in the Netherlands.
Yearly, approximately 10% of donors are no longer
available to donate, creating a continuous need for a signifi-
cant number of newly HLA-typed donors each year. Current
practice is annual recruitment among all 18- to 35-year-old
donors for HLA typing, without further selection. It is
expected that in the near future the availability of low-cost
genotyping platforms will vastly expand the availability of
HLA-typed platelet donors. Until genotyping of all new
donors becomes standard practice, it is wise to genotype
donors who are expected to increase the genetic diversity of
the donor population. The majority of Dutch blood and
platelet donors are of Caucasian origin, whereas a relatively
large proportion of patients for whom five or fewer donors
were available had a non-Caucasian background, predomi-
nantly African American. The preponderance of non-
Caucasian patients in the group with insufficient donors
suggests that additional typing and recruitment among eth-
nic minorities could increase the likelihood to find a com-
patible donor, as it would increase the genetic variability
among the donor population. Blood donorship from immi-
grants of mainly African ancestry could be stimulated using
specific campaigns to increase awareness and to overcome
differences in expectations regarding donorship.21 Cur-
rently, we are investigating to what extent it is possible to
register the ethnicity of a donor to target the typing of new
platelet donors. Besides, knowledge of the red blood cell
(RBC) phenotype of the current blood donor population
could be used. For instance, a large proportion of Dutch
blood donors is being typed for the presence of Duffy anti-
gens Fya and Fyb. The Fya–, Fyb– phenotype has proven to
be an accurate marker to identify donors with an African
background.22 Moreover, this method seems to be more
Fig. 3. Most likely population of origin for haplotypes with ≤5
donors and for haplotypes with ≥30 donors.
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accurate than self-reported race.23 Although only a small
portion of the total donor population has a Fya–, Fyb– pheno-
type, this group of donors likely add new HLA phenotypes to
our current platelet donor population, in which mainly
donors of African American origin are underrepresented.
Nevertheless, the HLA system is highly polymorphic.
So, even with increasing genetic variability, disparities
between patients and donors will sustain, and as a conse-
quence, providing completely HLA-matched platelets to
every patient with antibodies will not be feasible.24 The ben-
efits of additional typing of ethnic minorities would differ
per population of origin. It would be especially suitable for
patients from regions with limited genetic variability, mainly
Asia.25 In contrast, finding a compatible donor for an Afri-
can American patient will always be more challenging, as
this population has a very high degree of genetic variability
compared to other populations.8
In conclusion, although a large donor population is
available for donation of HLA-matched platelets, adequate
transfusion support could not be guaranteed for 10% of
refractory patients. Promoting blood donorship among resi-
dents of non-Caucasian origin and HLA typing of active
blood donors with rare RBC phenotypes can be useful strat-
egies to increase the availability of matched donors for our
refractory patients.
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